Gene Therapy For Retinal Diseases Market Size, Share & Trends Analysis Report By Indication (Choroideremia (CHM), Leber Congenital Amaurosis, Leber’s Hereditary Optic Neuropathy, X-Linked Retinitis Pigmentosa, and Other Indications), Region And Segment Forecasts, 2023-2031.

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Gene Therapy for Retinal Diseases Market Snapshot Chapter 4. Global Gene Therapy for Retinal Diseases Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Penetration & Growth Prospect Mapping 4.6. Epidemiology: Incidence Prevalence Analysis 2019 4.6.1. Choroideremia (CHM) 4.6.2. Leber congenital amaurosis 4.6.3. Leber's hereditary optic neuropathy 4.6.4. Retinitis pigmentosa 4.6.5. X-linked retinitis pigmentosa 4.6.6. X-linked retinoschisis 4.6.7. Usher syndrome type 1B 4.6.8. Stargardt disease 4.6.9. Achromatopsia 4.6.10. Neovascular/age-related macular degeneration 4.7. Clinical Trial/Pipeline Analysis 4.8. Industry Analysis – Porter's Five Forces Analysis 4.9. Technology Advancement in Gene Therapy for Retinal Diseases Market Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis 5.1. Indication Type & Market Share, 2020 & 2030 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Indication: 5.2.1. Choroideremia (CHM) 5.2.2. Leber congenital amaurosis 5.2.3. Leber's hereditary optic neuropathy 5.2.4. Retinitis pigmentosa 5.2.5. X-linked retinitis pigmentosa 5.2.6. X-linked retinoschisis 5.2.7. Usher syndrome type 1B 5.2.8. Stargardt disease 5.2.9. Achromatopsia 5.2.10. Neovascular/age-related macular degeneration 5.2.11. Other Indication Chapter 6. Gene Therapy for Retinal Diseases Market Segmentation 3: Regional Estimates & Trend Analysis 6.1. North America 6.1.1. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by Indication, 2020-2030 6.1.2. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2030 6.1.2.1. U.S. 6.1.2.2. Canada 6.2. Europe 6.2.1. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030 6.2.2. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030 6.2.2.1. Germany 6.2.2.2. Poland 6.2.2.3. France 6.2.2.4. Italy 6.2.2.5. Spain 6.2.2.6. UK 6.2.2.7. Rest of Europe 6.3. Asia Pacific 6.3.1. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030 6.3.2. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030 6.3.2.1. China 6.3.2.2. India 6.3.2.3. Japan 6.3.2.4. Australia 6.3.2.5. Rest of Asia Pacific 6.4. Latin America 6.4.1. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million) 6.4.2. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2030 6.4.2.1. Brazil 6.4.2.2. Rest of Latin America 6.5. MEA 6.5.1. MEA revenue Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million) 2020-2030 Chapter 7. Competitive Landscape 7.1. Major Mergers and Acquisitions/Strategic Alliances 7.2. Company Profiles 7.2.1. Applied Genetic Technologies Corporation 7.2.2. Adverum Biotechnologies 7.2.3. ProQR Therapeutics 7.2.4. MeiraGTx Limited. 7.2.5. Oxford BioMedica 7.2.6. Horama S.A. 7.2.7. Gensight Biologics 7.2.8. Regenxbio Inc. 7.2.9. Spark Therapeutics, Inc. 7.2.10. Genzyme (Sanofi) 7.2.11. Novartis Pharmaceuticals 7.2.12. Nightstar Therapeutics (Biogen) 7.2.13. Hemera Biosciences 7.2.14. ViGeneron GmbH 7.2.15. Allergan 7.2.16. Eyevensys 7.2.17. Clearside Biomedical 7.2.18. IVERIC bio, Inc. 7.2.19. Other Prominent Players